| Liu, James |
| Recruiting | 3 | 14000 | Europe, Canada, US, RoW | Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml | Novartis Pharmaceuticals | Primary Prevention of Atherosclerotic Cardiovascular Disease | 03/29 | 03/29 | | |
| Recruiting | 2 | 60 | US | Hypofractionated Stereotactic Radiosurgery | H. Lee Moffitt Cancer Center and Research Institute | Brain Metastases, Brain Lesion | 08/25 | 08/26 | | |
NCT04588545: Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease |
|
|
| Recruiting | 1/2 | 39 | US | Radiation Therapy, Pertuzumab, Trastuzumab | H. Lee Moffitt Cancer Center and Research Institute, Genentech, Inc. | HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease | 07/25 | 07/25 | | |
MCC-20899, NCT04923542: Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases |
|
|
| Recruiting | 1/2 | 31 | US | Stereotactic Radiosurgery (SRS), Abemaciclib, Verzenio, Ramiven, Endocrine therapy, hormone therapy | H. Lee Moffitt Cancer Center and Research Institute, Eli Lilly and Company | Brain Metastases, HR+ Metastatic Breast Cancer | 12/24 | 12/24 | | |
NCT05664243: A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma |
|
|
| Active, not recruiting | 1/2 | 4 | US | Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified gamma-delta T cells | In8bio Inc. | Glioblastoma | 12/25 | 12/25 | | |
NCT03927274: Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma |
|
|
| Terminated | 1 | 3 | US | Topotecan | H. Lee Moffitt Cancer Center and Research Institute | Glioma of Brain | 05/23 | 05/23 | | |
NCT06463184: Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG) |
|
|
| Withdrawn | 1 | 12 | NA | Xevinapant, Debio 1143 | H. Lee Moffitt Cancer Center and Research Institute, EMD Serono Research & Development Institute, Inc. | Recurrent High-grade Glioma | 06/27 | 06/27 | | |
CA209-6D9, NCT05704933: Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases |
|
|
| Active, not recruiting | 1 | 16 | US | Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab + Relatlimab, Opdualag, Standard of Care Craniotomy | H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb | Metastatic Melanoma, Metastasis to Brain | 06/24 | 06/25 | | |
NCT05898334: Impact of Biophoton Generator on Chronic-Stroke Patients' Recovery |
|
|
| Completed | N/A | 48 | US | Active Biophoton Generators, Inactive Biophoton Generators | First Institute of All Medicines | Chronic Stroke, Paralysis | 06/24 | 06/24 | | |
| Recruiting | N/A | 152 | US | Standard Implantation, Tied off Tube | Washington University School of Medicine, American Glaucoma Society, University of Pittsburgh | Glaucoma Eye, Ahmed Glaucoma Valve Implantation | 12/24 | 01/25 | | |
| Lyman, Aliceson |
| Recruiting | 3 | 14000 | Europe, Canada, US, RoW | Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml | Novartis Pharmaceuticals | Primary Prevention of Atherosclerotic Cardiovascular Disease | 03/29 | 03/29 | | |
| Estevez, Rogers |
| Recruiting | 3 | 14000 | Europe, Canada, US, RoW | Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml | Novartis Pharmaceuticals | Primary Prevention of Atherosclerotic Cardiovascular Disease | 03/29 | 03/29 | | |
| Lobdell, Caitlin |
| Recruiting | 3 | 14000 | Europe, Canada, US, RoW | Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml | Novartis Pharmaceuticals | Primary Prevention of Atherosclerotic Cardiovascular Disease | 03/29 | 03/29 | | |
